TVTX
Travere Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$50.39Close
$4.6BMarket cap
$26.79 – $67.5252-week range
Nov 2, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 82 · stronger than 82% of stocks over 12 months
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 25% below its 52-week high
- Results soon Nov 2, 2026, in 1 day
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
25%
1wk
up 0.6%
price change
1mo
down 14.4%
price change
12-month return
up 70%
market up 11% ·
its own up 57%
F-score
7 / 9
Strong
Altman Z
3.22
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
39.9×
price / book
Earnings yield
down 1.4%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
up 110%
year on year
EPS growth
—
latest quarter
Sales growth
up 48%
latest quarter · -7 pts
ROE
down 29%
return on equity
Free cash margin
up 8%
$37.8M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- issued more shares
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
- assets working harder
Repair signals
- FCF turned positive ($-237M → $38M)
- Gross margin 96.7% → 97.9%
Trade setup
ATR%
4.5%
$2.28 a day · 2×ATR $45.82
RS
82 / 99
vs the universe
Trend
5 / 8
under the 150/200-day, under the 50-day, over 25% off the high
Relative volume
0.7×
vs 50-day average
Up/down volume
0.75
50 sessions
Implied move
—
no option chain · report Nov 2, 2026
Contractions
2
25% → 11%
Pivot
$55.57
9.3% below
Volume dry-up
1.2×
10 vs 50 sessions
Trend template · 5 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 4.0% over the year, from 87m to 91m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026+13% vs market2 sessions after results
Financials
- Gross 98%
- Net -5%
- Free cash 8%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $198.3M | $131.8M | $109.5M | $145.2M | $233.2M | $490.7M |
| Gross margin | 97% | 97% | 96% | 92% | 97% | 98% |
| Operating income | -$176.2M | -$199.4M | -$319.8M | -$388.1M | -$323.8M | -$62.8M |
| Net income | -$169.4M | -$180.1M | -$278.5M | -$111.4M | -$321.5M | -$25.5M |
| Net margin | -85% | -137% | -254% | -77% | -138% | -5% |
| Earnings per share | -$3.56 | -$3.01 | -$4.37 | -$1.50 | -$4.08 | -$0.29 |
| Free cash flow | -$49.5M | -$19.9M | -$186.5M | -$280.7M | -$237.5M | $37.8M |
| Free cash margin | -25% | -15% | -170% | -193% | -102% | 8% |
| Cash | $84.8M | $165.8M | $61.7M | $58.2M | $58.5M | $93.0M |
| Shareholders' equity | $211.2M | $302.1M | $42.9M | $200.8M | $59.1M | $114.8M |
| Shares outstanding | 52.25m | 62.49m | 64.29m | 75.37m | 87.45m | 90.92m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 4, 2026 | Quarterly ↗ | Mar 31, 2026 | 34d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Oct 30, 2025 | Quarterly ↗ | Sep 30, 2025 | 30d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 21, 2025 | Annual ↗ | Dec 31, 2024 | 52d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 6, 2024 | Quarterly ↗ | Mar 31, 2024 | 36d |
| Feb 20, 2024 | Annual ↗ | Dec 31, 2023 | 51d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 21, 2026 | Director or officer change ↗ |
| Aug 4, 2026 | Results ↗ |
| Jul 9, 2026 | Director or officer change ↗ |
| Jun 16, 2026 | Director or officer change ↗ |
| Jun 2, 2026 | Material agreement ↗ |
| May 21, 2026 | Director or officer change · Shareholder vote ↗ |
| May 11, 2026 | Material agreement · New obligation · Unregistered share sale · Other events ↗ |
| May 4, 2026 | Results ↗ |
| Apr 14, 2026 | Other events ↗ |
| Feb 19, 2026 | Results ↗ |
| Jan 13, 2026 | Other events ↗ |
| Jan 12, 2026 | Results ↗ |